Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

Mia Aaboe Jørgensen, Stefano Ugel, Mie Linder Hübbe, +15

Cancer Immunology Research

TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer

Maria Perez-Penco, Stine Emilie Weis-Banke, Aimilia Schina, +13

Journal for ImmunoTherapy of Cancer

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

Shamaila Munir Ahmad, Evelina Martinenaite, Morten Orebo Holmström, +11

OncoImmunology

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

Stine Emilie Weis-Banke, Mie Linder Hübbe, Morten Orebo Holmström, +10

OncoImmunology

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells

Stine Emilie Weis-Banke, Thomas Landkildehus Lisle, Maria Perez-Penco, +12

Journal for ImmunoTherapy of Cancer

Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation

Mia Aaboe Jørgensen, Morten Orebo Holmström, Evelina Martinenaite, +3

OncoImmunology